FDA Workshop Highlights First B-cell Therapy for Pediatric Genetic Disorder
The U.S. Food and Drug Administration (FDA) is hosting a workshop titled 'Advancing Pediatric Cell and Gene Therapy Clinical Trials,' where Immusoft will present a clinical case review of the world's first engineered B-cell therapy administered to a pediatric patient. This therapy, known as ISP-001, is designed to treat Mucopolysaccharidosis type I, a rare genetic disorder caused by a deficiency of the enzyme α-L-iduronidase. The therapy aims to overcome limitations of current enzyme replacement therapies and address safety concerns associated with stem cell therapy. ISP-001 utilizes the patient's own B cells to produce therapeutic levels of the enzyme, and has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the FDA. 
